Avidity Biosciences Inc’s filing revealed that its Chief Commercial Officer Mosbrooker Eric unloaded Company’s shares for reported $0.3 million on Oct 03 ’25. In the deal valued at $45.38 per share,6,562 shares were sold. As a result of this transaction, Mosbrooker Eric now holds 55,000 shares worth roughly $2.65 million.
Then, Hughes Steven George sold 2,208 shares, generating $89,601 in total proceeds. Upon selling the shares at $40.58, the Chief Medical Officer now owns 38,867 shares.
Before that, McCarthy Teresa sold 15,000 shares. Avidity Biosciences Inc shares valued at $621,142 were divested by the Chief Human Resources Officer at a price of $41.41 per share. As a result of the transaction, McCarthy Teresa now holds 97,130 shares, worth roughly $4.67 million.
Roth Capital initiated its Avidity Biosciences Inc [RNA] rating to a Buy in a research note published on September 17, 2025; the price target was $62. Bernstein began covering RNA with “an Outperform” recommendation on June 24, 2025. Wolfe Research started covering the stock on June 17, 2025. It rated RNA as “an Outperform”.
Price Performance Review of RNA
On Tuesday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock fall -1.70% to $48.13. Over the last five days, the stock has gained 2.51%. Avidity Biosciences Inc shares have risen nearly 8.84% since the year began. Nevertheless, the stocks have risen 65.51% over the past one year.
How much short interest is there in Avidity Biosciences Inc?
A steep rise in short interest was recorded in Avidity Biosciences Inc stocks on 2025-09-30, growing by 3.18 million shares to a total of 20.75 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 17.57 million shares. There was a rise of 15.32%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 11, 2025 when Raymond James began covering the stock and recommended ‘”a Strong buy”‘ rating along with a $65 price target.
